Company intelligence / Profile preview

Embarcatec

Ownership: Private
Development stage: Other

Overview

Embark Biotech developed novel small molecule therapeutics targeting cardiometabolic diseases with an emphasis on increasing energy expenditure. Their lead program targeted obesity through modulation of specific neuropeptide pathways. The company was acquired by Novo Nordisk in August 2023 before advancing any programs into late-stage clinical development

Therapeutic areas: Metabolic Disorders
Modalities: Small molecule
Industry: Biotech

Partnerships

Novo Nordisk Foundation Center for Basic Metabolic Research (academic collaboration/investor)

Beyond the preview

Go deeper on Embarcatec.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Embarcatec.

Explore the full profile